ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024GlobeNewsWire • 01/19/24
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing CollaborationGlobeNewsWire • 01/05/24
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic AssetsGlobeNewsWire • 12/08/23
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA EditingGlobeNewsWire • 11/06/23
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/28/23
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/07/23
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic AssetsGlobeNewsWire • 08/01/23
ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing SummitGlobeNewsWire • 07/06/23
Will ProQR (PRQR) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 04/27/23
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D EventGlobeNewsWire • 03/29/23
ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA EditingGlobeNewsWire • 03/14/23